Entera Bio (NASDAQ:ENTX) Director Buys $26,000.00 in Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Geno Germano acquired 20,000 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average cost of $1.30 per share, with a total value of $26,000.00. Following the transaction, the director owned 40,000 shares in the company, valued at approximately $52,000. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Entera Bio Price Performance

NASDAQ:ENTX opened at $1.27 on Friday. Entera Bio Ltd. has a one year low of $1.00 and a one year high of $3.22. The business has a fifty day moving average price of $1.46 and a 200-day moving average price of $1.95. The firm has a market capitalization of $58.24 million, a price-to-earnings ratio of -5.08 and a beta of 1.83.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ENTX. Superstring Capital Management LP bought a new stake in shares of Entera Bio in the fourth quarter worth about $33,000. Citadel Advisors LLC boosted its stake in Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC boosted its stake in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC grew its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after buying an additional 19,601 shares in the last quarter. Institutional investors own 14.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen raised Entera Bio to a “sell” rating in a research note on Saturday, December 27th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Monday, February 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.